Page last updated: 2024-10-17

lactic acid and Intermittent Claudication

lactic acid has been researched along with Intermittent Claudication in 20 studies

Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.

Intermittent Claudication: A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE.

Research Excerpts

ExcerptRelevanceReference
"The TcPO2 electrode was attached to the dorsum of the foot."2.67Transcutaneous oxygen pressure measurements in patients with intermittent claudication. ( Celsing, F; Eriksson, M; Rosfors, S, 1994)

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19909 (45.00)18.7374
1990's4 (20.00)18.2507
2000's6 (30.00)29.6817
2010's0 (0.00)24.3611
2020's1 (5.00)2.80

Authors

AuthorsStudies
Semporé, WY1
Hersant, J1
Ramondou, P1
Hamel, JF1
Abraham, P1
Henni, S1
Parr, B1
Noakes, TD1
Derman, EW1
Zwierska, I1
Walker, RD1
Choksy, SA1
Male, JS1
Pockley, AG1
Saxton, JM1
Westman, B1
Johansson, G1
Söderlund, K1
Wernerman, J1
Hammarqvist, F1
Tuner, SL1
Easton, C1
Wilson, J1
Byrne, DS1
Rogers, P1
Kilduff, LP1
Kingsmore, DB1
Pitsiladis, YP1
Maass, U4
Alexander, K3
Ruell, PA1
Imperial, ES1
Bonar, FJ1
Thursby, PF1
Gass, GC1
Qvarfordt, P1
Eklöf, B2
Ohlin, P1
Plate, G1
Saltin, B1
Forconi, S1
Pieragalli, D1
Acciavatti, A1
Del Bigo, C1
Galigani, C1
Ralli, L1
Guerrini, M1
Di Perri, T1
Sjöström, M1
Neglén, P1
Fridén, J1
Goller, B3
Grothe, R1
Schneider, B2
Rosfors, S1
Celsing, F1
Eriksson, M1
Chello, M1
Mastroroberto, P1
Celi, V1
Romano, F1
Marchese, AR1
Colonna, A1
Tan, KH1
Cotterrell, D1
Sykes, K1
Sissons, GR1
de Cossart, L1
Edwards, PR1
Coolen, SA1
Wijnen, MH1
Reijenga, JC1
Vader, HL1
Roumen, RM1
Huf, FA1
Rexroth, W1
Hild, R1
Grote, R2
Nehmiz, G1
Brevetti, G1
Chiariello, M1
Ferulano, G1
Policicchio, A1
Nevola, E1
Rossini, A1
Attisano, T1
Ambrosio, G1
Siliprandi, N1
Angelini, C1
Walker, PM1
Harris, KA1
Tanner, WR1
Harding, R1
Romaschin, AD1
Mickle, DA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172]Phase 4164 participants (Actual)Interventional2008-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Claudication Onset Time at Day 180

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine1.065
Cilostazol + Placebo0.896

Change From Baseline in Claudication Onset Time at Day 90

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine1.001
Cilostazol + Placebo0.815

Change From Baseline in Peak Walking Time (PWT) at Day 180

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine0.241
Cilostazol + Placebo0.134

Change From Baseline in Peak Walking Time at Day 180

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine0.267
Cilostazol + Placebo0.145

Change From Baseline in Peak Walking Time at Day 90

Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90

InterventionLog Minutes (Mean)
Cilostazol + L-Carnitine0.166
Cilostazol + Placebo0.139

Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 180

Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180

Interventionscore on a scale (Mean)
Cilostazol + L-Carnitine13.20
Cilostazol + Placebo6.57

Change From Baseline in Walking Impairment Questionnaire for Walking Distance at Day 90

Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90

Interventionscore on a scale (Mean)
Cilostazol + L-Carnitine12.98
Cilostazol + Placebo10.01

Trials

5 trials available for lactic acid and Intermittent Claudication

ArticleYear
Cardiopulmonary responses to treadmill and cycle ergometry exercise in patients with peripheral vascular disease.
    Journal of vascular surgery, 2008, Volume: 47, Issue:1

    Topics: Adult; Bicycling; Cardiovascular System; Exercise Test; Exercise Tolerance; Heart Rate; Humans; Inte

2008
Transcutaneous oxygen pressure measurements in patients with intermittent claudication.
    Clinical physiology (Oxford, England), 1994, Volume: 14, Issue:4

    Topics: Aged; Blood Gas Monitoring, Transcutaneous; Exercise Test; Heart Rate; Humans; Intermittent Claudica

1994
Reduction by indobufen of neutrophil activation in peripheral arterial occlusive disease.
    Journal of cardiovascular pharmacology, 1996, Volume: 27, Issue:3

    Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Arterial Occlusive Diseases; Cyclooxygenase Inhibitors; H

1996
A new method for measuring oxidative stress in claudicants during strenuous exercise using free radical derivatives of antipyrine as indicators: a pilot study.
    Annals of clinical and laboratory science, 2002,Spring, Volume: 32, Issue:2

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Exercise; Female; Free Radicals; Humans;

2002
Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study.
    Circulation, 1988, Volume: 77, Issue:4

    Topics: Carnitine; Clinical Trials as Topic; Double-Blind Method; Exercise Test; Female; Humans; Intermitten

1988

Other Studies

15 other studies available for lactic acid and Intermittent Claudication

ArticleYear
Exercise Oximetry Correlates Better With Exercise-Induced Lactate Increase, than Ankle Brachial Index or Walking Time, in Vascular Claudicants.
    Angiology, 2023, Volume: 74, Issue:6

    Topics: Ankle Brachial Index; Blood Gas Monitoring, Transcutaneous; Exercise Test; Humans; Intermittent Clau

2023
Factors predicting walking intolerance in patients with peripheral arterial disease and intermittent claudication.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2008, Volume: 98, Issue:12

    Topics: Exercise Test; Exercise Tolerance; Follow-Up Studies; Humans; Intermittent Claudication; Lactic Acid

2008
Relative tolerance to upper- and lower-limb aerobic exercise in patients with peripheral arterial disease.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2006, Volume: 31, Issue:2

    Topics: Aged; Aged, 80 and over; Blood Pressure; Exercise Therapy; Exercise Tolerance; Extremities; Female;

2006
Muscle glutathione metabolism during ischemia and reperfusion in patients undergoing aorto-bifemoral bypass surgery.
    Acta anaesthesiologica Scandinavica, 2006, Volume: 50, Issue:6

    Topics: Aged; Amino Acids; Anesthesia, General; Energy Metabolism; Female; Glutathione; Humans; Intermittent

2006
Effect of treadmill exercise on blood gases and acid-base balance in patients with intermittent claudication.
    Zeitschrift fur Kardiologie, 1983, Volume: 72, Issue:9

    Topics: Acid-Base Equilibrium; Adult; Aged; Bicarbonates; Carbon Dioxide; Exercise Test; Female; Hemodynamic

1983
Intermittent claudication. The effect of physical training on walking tolerance and venous lactate concentration.
    European journal of applied physiology and occupational physiology, 1984, Volume: 52, Issue:4

    Topics: Aged; Exercise Test; Exercise Therapy; Female; Humans; Intermittent Claudication; Lactates; Lactic A

1984
Intramuscular pressure, blood flow, and skeletal muscle metabolism in patients with venous claudication.
    Surgery, 1984, Volume: 95, Issue:2

    Topics: Adenosine Triphosphate; Adolescent; Adult; Aged; Blood Pressure; Chronic Disease; Female; Humans; Il

1984
Positive effect of oral buflomedil on exercise-induced haemorheological damage and on claudication distance in peripheral obliterative arterial disease patients.
    The Journal of international medical research, 1984, Volume: 12, Issue:3

    Topics: Administration, Oral; Arterial Occlusive Diseases; Blood Viscosity; Female; Humans; Hydrogen-Ion Con

1984
Human skeletal muscle metabolism and morphology after temporary incomplete ischaemia.
    European journal of clinical investigation, 1982, Volume: 12, Issue:1

    Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Adult; Aged; Constriction; F

1982
[The walking-through phenomenon in arterial occlusive disease].
    VASA. Zeitschrift fur Gefasskrankheiten, 1995, Volume: 24, Issue:3

    Topics: Adult; Aged; Arterial Occlusive Diseases; Exercise Test; Exercise Therapy; Glycolysis; Humans; Inter

1995
Exercise training for claudicants: changes in blood flow, cardiorespiratory status, metabolic functions, blood rheology and lipid profile.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2000, Volume: 20, Issue:1

    Topics: Aged; Blood Flow Velocity; Blood Pressure; Cholesterol, HDL; Energy Metabolism; Exercise Test; Exerc

2000
[Biochemical modifications in stress ischemia of the calf muscles].
    VASA. Supplementum, 1991, Volume: 32

    Topics: Alanine; Ammonia; Energy Metabolism; Humans; Hypoxanthine; Hypoxanthines; Intermittent Claudication;

1991
Lactate and pyruvate kinetics after treadmill exercise in patients with intermittent claudication.
    VASA. Zeitschrift fur Gefasskrankheiten, 1989, Volume: 18, Issue:3

    Topics: Adult; Aged; Exercise Test; Humans; Intermittent Claudication; Kinetics; Lactates; Lactic Acid; Male

1989
[Interval exercise in arterial occlusive disease].
    VASA. Zeitschrift fur Gefasskrankheiten, 1989, Volume: 18, Issue:3

    Topics: Energy Metabolism; Exercise Test; Humans; Intermittent Claudication; Lactates; Lactic Acid; Male; Mi

1989
Laboratory evaluation of patients with vascular occlusive disease.
    Journal of vascular surgery, 1985, Volume: 2, Issue:6

    Topics: Adenosine Triphosphate; Adult; Aged; Blood Pressure; Glycogen; Humans; Intermittent Claudication; Is

1985